Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile.
Saved in:
| Title: | Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile. |
|---|---|
| Authors: | Burban A; University of Bordeaux, CNRS, IBGC, UMR5095, Bordeaux, France., Tessier C; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France., Larroquette M; University of Bordeaux, CNRS, IBGC, UMR5095, Bordeaux, France., Guyon J; CHU of Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.; University of Bordeaux, INSERM, BPH, U1219, Bordeaux, France., Lubiato C; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France., Pinglaut M; University of Bordeaux, CNRS, IBGC, UMR5095, Bordeaux, France., Toujas M; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France., Galvis J; University of Bordeaux, CNRS, IBGC, UMR5095, Bordeaux, France., Dartigues B; Bordeaux Bioinformatic Center CBiB, University of Bordeaux, Bordeaux, France., Georget E; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France., Luchman HA; Department of Cell Biology and Anatomy, University of Calgary, Calgary, Alberta, Canada.; Arnie Charbonneau Cancer Institute and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada., Weiss S; Department of Cell Biology and Anatomy, University of Calgary, Calgary, Alberta, Canada.; Arnie Charbonneau Cancer Institute and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada., Cappellen D; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France., Nicot N; LuxGen Genome Center, Luxembourg Institute of Health, Laboratoire national de santé, Dudelange, Luxembourg., Klink B; LuxGen Genome Center, Luxembourg Institute of Health, Laboratoire national de santé, Dudelange, Luxembourg.; National Center of Genetics (NCG), Laboratoire National de Santé (LNS), Dudelange, Luxembourg.; Department of Cancer Research (DoCR), Luxembourg Institute of Health (LIH), Luxembourg, 1526, Luxembourg.; Department of Life Sciences and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg., Nikolski M; University of Bordeaux, CNRS, IBGC, UMR5095, Bordeaux, France.; Bordeaux Bioinformatic Center CBiB, University of Bordeaux, Bordeaux, France., Brisson L; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France., Mathivet T; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France., Bikfalvi A; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France. andreas.bikfalvi@u-bordeaux.fr., Daubon T; University of Bordeaux, CNRS, IBGC, UMR5095, Bordeaux, France. thomas.daubon@u-bordeaux.fr., Sharanek A; University of Bordeaux, INSERM, UMR1312, BRIC, BoRdeaux Institute of onCology, Bordeaux, France. ahmad.charanek@u-bordeaux.fr. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2025 Mar; Vol. 17 (3), pp. 469-503. Date of Electronic Publication: 2025 Feb 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
